We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
51
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.1M 0.49%
78,784
– –
TMO icon
52
Thermo Fisher Scientific
TMO
$210B
$13M 0.49%
29,461
-76,564
-72% -$31.6M
NVCR icon
53
NovoCure
NVCR
$1.88B
$13M 0.49%
116,845
-14,792
-11% -$1.18M
IQV icon
54
IQVIA
IQV
$37.6B
$13M 0.49%
82,266
– –
TECH icon
55
Bio-Techne
TECH
$11.2B
$12.8M 0.48%
206,840
– –
DGX icon
56
Quest Diagnostics
DGX
$25.7B
$12.6M 0.47%
109,659
+88,634
+422% +$10.5M
CI icon
57
Cigna
CI
$72.8B
$12.1M 0.45%
71,241
-8,747
-11% -$1.54M
ARNA
58
DELISTED
Arena Pharmaceuticals Inc
ARNA
$12M 0.45%
160,637
+72,635
+83% +$4.84M
WELL icon
59
Welltower
WELL
$165B
$11.2M 0.42%
203,083
– –
ACAD icon
60
Acadia Pharmaceuticals
ACAD
$4.48B
$10.3M 0.39%
250,743
– –
HCA icon
61
HCA Healthcare
HCA
$86.3B
$10.2M 0.38%
81,933
-1,900
-2% -$235K
ELV icon
62
Elevance Health
ELV
$82.7B
$9.97M 0.37%
37,133
-3,109
-8% -$837K
BAX icon
63
Baxter International
BAX
$14.3B
$9.81M 0.37%
122,023
– –
JAZZ icon
64
Jazz Pharmaceuticals
JAZZ
$16.1B
$9.62M 0.36%
67,456
– –
MTD icon
65
Mettler-Toledo International
MTD
$28.8B
$9.46M 0.35%
9,800
+3,677
+60% +$3.41M
GRTX
66
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$9.42M 0.35%
1,041,845
– –
ZTS icon
67
Zoetis
ZTS
$31.7B
$9.35M 0.35%
56,521
-24,600
-30% -$3.78M
NVO
68
Novo Nordisk
NVO
$196B
$9.3M 0.35%
268,010
– –
OHI icon
69
Omega Healthcare
OHI
$14.5B
$9.18M 0.34%
306,433
– –
IONS icon
70
Ionis Pharmaceuticals
IONS
$9.14B
$9.17M 0.34%
193,201
– –
IOVA icon
71
Iovance Biotherapeutics
IOVA
$1.97B
$8.92M 0.33%
271,073
– –
DOC
72
DELISTED
PHYSICIANS REALTY TRUST
DOC
$8.88M 0.33%
495,733
– –
VTR icon
73
Ventas
VTR
$46.1B
$8.73M 0.33%
208,108
– –
FATE icon
74
Fate Therapeutics
FATE
$303M
$8.69M 0.33%
217,462
+31,790
+17% +$1.11M
ONC
75
BeOne Medicines Ltd
ONC
$33.3B
$8.1M 0.3%
28,280
-46,704
-62% -$11M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.